Baxter International Inc
baxter.comBaxter International Inc (NYSE: BAX) is a medical products company that develops, manufactures, and sells hospital and renal care products used in acute and chronic care settings. Revenue is generated through the direct sale of medical devices, intravenous therapies, pharmaceuticals, and nutritional products to hospitals, clinics, and other healthcare providers. As of its 10-K filed February 12, 2026, Baxter completed a significant portfolio restructuring, selling its Kidney Care business (now Vantive Health LLC) to Carlyle Group affiliates on January 31, 2025 for approximately $3.71 billion in pre-tax cash proceeds. Baxter used the net after-tax proceeds, along with other sources, to repay $3.81 billion in legacy indebtedness during FY2025. The Kidney Care segment is reported as discontinued operations in Baxter's FY2025 consolidated financials, meaning the continuing business is now focused on its remaining hospital products and therapies segments.
Products & Services
Intravenous therapies, hospital pharmaceuticals, nutritional products, medical devices, and renal care products (Kidney Care segment divested to Vantive Health LLC on January 31, 2025, reported as discontinued operations in FY2025 financials per 10-K filed 2026-02-12).
Revenue Model
Transactional product sales to hospitals, clinics, and healthcare institutions. Products include medical devices, IV solutions, and pharmaceuticals sold directly to healthcare providers.
Customers & Markets
Hospitals, acute care clinics, and other healthcare institutions. End markets include acute hospital care settings.
Geographic Exposure
Not specified in the available filing excerpts.
Financial Snapshot
Loading...
